参考文献
[1]中华医学会心血管病学分会，中华心血管病杂志编辑委员会，中国心肌病诊断与治疗建议工作组.心肌病诊断与治疗建议.中华心血管病杂志，2007，35：3-16.
[2]中华医学会心血管病学分会，中华心血管病杂志编辑委员会，室间隔心肌消融术治疗专题组.肥厚型梗阻性心肌病室间隔心肌消融术的中国专家共识.中华心血管病杂志，2011，39：886-891.
[3]闫丽荣，樊朝美.心尖肥厚型心肌病的研究进展.中华心血管病杂志，2011，39：970-972.
[4]包镜汝，姚焰.致心律失常性右室心肌病致病基因研究进展.中华心律失常学杂志，2011，15：309-311.
[5]刘文玲，胡大一.致心律失常性右室心肌病研究的最新进展：欧洲心律失常学会2009年报道.中国心脏起搏与心电生理杂志，2009，23：202-203.
[6]乔青，华伟.致心律失常性右室心肌病的治疗学进展.中华心律失常学杂志，2010，14：465-468.
[7]BernardJ.Gersh,MB,ChB,et al.2011ACCF/AHA Guidelines for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy:Executive Summary a Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Gguidelines Developed in Collaboration with the American Association for thoracic Surgery,American Society of Echocardiography,American Society of Nuclear Cardiology,Heart Failure Society of American,Heart Rhythm Society,Society for Cardiovascular Angiography and Interventions,and Society of Thoracic Surgeons.J Am Coll Cardiol,2011,58:2703-2738.
[8]Spirito P，Maron BJ.肥厚型心肌病猝死危险因素分层.中华心血管病杂志，2009，37：294-297.
[9]Maron BJ.Sudden death in hypertrophic cardiomyopathy.J Cardiovasc Transl Res,2009,2:368-380.
[10]Maron BJ，Spirito P.肥厚型心肌病猝死的预防：肥厚型心肌病患者除颤器置入.中华心血管病杂志，2009，37：297-302.
[11]Choi EY,Rim SJ,Ha JW,et al.Phenotypic spectrum and clinical characteristics of apical hypertrophic cardiomyopathy:multicenter echo-Doppler study.Cardiology,2008,110:53-61.(https://www.daowen.com)
[12]Leonardi RA,Kransdorf EP,Simel DL,et al.Meta-analyses of septal reduction therapies for obstructive hypertrophic cardiomyopathy:comparative rates of overall mortality and sudden cardiac death after treatment.Circ Cardiovasc Interv,2010,3:97-104.
[13]Nagueh SF,Groves BM,Schwartz L,et al.Alcohol septal ablation for the treatment of hypertrophic obstructive cardiomyopathy.A multicenter North American registry.J Am Coll Cardiol,2011,58:2322-2328.
[14]Leal S,Galeote G,Jiménez-Valero S,et al.Percutaneous alcohol septal ablation for hypertrophic obstructive cardiomyopathy:technical review and long-term clinical and echocardiographic outcomes.Rev Port Cardiol,2012,4:4.
[15]Peters S.Advances in the diagnostic management of arrhythmogenic tight ventricular dysplasiacardiomyopathy.Int JCardiol,2006,113:4-11.
[16]Zipes DP,Camm AJ,Borggrefe M,et al.ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death:a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines(Writing committee to develop Guidelines for Management of Patients With Vebtricular Arrhythmias and the Prevention of Sudden Cardiac Death):developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society.Circulation,2006,114:e385-e484.
[17]Kaski JP,Tome-Esteban MT,Mead-Regan S,et al.B-type natriuretic peptide predicts disease severity in children with hypertrophic cardiomyopathy.Heart,2008,94:1307-1311.
[18]Kimmelstiel C，Krishnamurthy B，Weintraub A，et al.酒精室间隔消融术与肥厚型心肌病.中华心血管病杂志，2009，37：1074-1077.
[19]Agarwal S,Tuzcu EM,Desai MY,et al.Updated meta-analysis of septal alcohol ablation versus myectomy for hypertrophic cardiomyopathy.J Am Coll Cardiol,2010,55:823-834.
[20]Alam M,Dokainish H,Lakkis NM,et al.Hypertrophic obstructive cardiomyopathy-alcohol septal ablation vs.myectomy:a meta-analysis.Eur Heart J,2009,30:1080-1087.
[21]Elliott P,Andersson B,Arbustini E,et al.Classification of the cardiomyopathies:a position statement from the European Society of Cardiology working group on myocardial and pericardial diseases.Eur Heart J,2008,29:270-276.